← Leaderboards
Brian K Law
Vanderbilt University
$2,053,690
Attributed
$2,053,690
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $388.8K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,053,690 · 3
By mechanism
R01$1,290,233 · 1
R21$763,457 · 2
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Cyndya Adriana Shibao$7,503,835
- Digna R Velez Edwards$11,329,288
- Tom A Elasy$8,788,804
- Lynn M Matrisian$19,522,211
- Ann Richmond$15,857,391
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMediatingSignal TransductionIn VivoAntineoplastic AgentsTumorEpidermal Growth Factor ReceptorDrug ResistanceErbb2 GeneClinical TrialsDisulfidesDown-RegulationAnimalsEnzyme ActivityCell ProliferationCyclin Dependent KinaseApoptosisCancer CellApoptoticCell DeathBindingCell SurfaceDisulfide BondAnti-Cancer
Grant awards (8)
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities$165,076
R21 · FY2024 · CA · contact PI
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities$209,624
R21 · FY2023 · CA · contact PI
Regulation of Death Receptor 5 folding and apoptotic signaling by AGR2$388,757
R21 · FY2020 · CA · contact PI
Rapamycin Potentiates TGFb Tumor Suppressor Function$245,569
R01 · FY2007 · CA · contact PI
Rapamycin Potentiates TGFb Tumor Suppressor Function$252,904
R01 · FY2006 · CA · contact PI
Rapamycin Potentiates TGFb Tumor Suppressor Function$258,990
R01 · FY2005 · CA
Rapamycin Potentiates TGFb Tumor Suppressor Function$263,990
R01 · FY2004 · CA
Rapamycin Potentiates TGFb Tumor Suppressor Function$268,780
R01 · FY2003 · CA